EFS, defined as time from randomisation to BC relapse, contralateral BC, other malignant neoplasms or death from any cause, for each molecular group, including the comparison of TCHP versus T-DXd in HER2-enriched patients, and at the two patient groups of the initial randomisation of TCHP versus T-DXd. This evidence concerns the gene ERBB2 and cancer.